- Push-out Score determined
- After about 19 years in the position
- Accolades, praise and thanks for Maraganore
- Yvonne Greenstreet taking over
- Maraganore said 124 words
(exechange) — Cambridge, Massachusetts, October 28, 2021 — John Maraganore, chief executive of Alnylam, leaves. As announced by Alnylam Pharmaceuticals Inc. in a news release and in a regulatory filing published on Thursday, October 28, 2021, John M. Maraganore leaves his post as chief executive officer at the RNAi therapeutics company, after about 19 years in the role, effective December 31, 2021.
It is the end of an era.
John Maraganore’s duties as CEO will be taken over by Yvonne L. Greenstreet, currently President and Chief Operating Officer at Alnylam Pharmaceuticals Inc.
“This is the right time”
John Maraganore’s departure from the CEO post is explained as follows. John Maraganore said: “I have decided that this is the right time to transition my leadership at year end to focus my next chapter on helping other entrepreneurs and companies advance new frontiers of medicine.”
Precise information regarding John Maraganore’s future plans was not immediately available.
Alnylam said: “Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today the planned CEO transition of John Maraganore, Ph.D., to Yvonne Greenstreet, MBChB, at year-end 2021.”
Alnylam further said: “[F]ollowing nearly 19 years of service, John M. Maraganore, Ph.D., will depart from his position as Chief Executive Officer of the Company and as a member of the Board, effective December 31, 2021.”
Share price increase since October 2016
The announcement follows an increase in Alnylam Pharmaceuticals Inc.’s share price of 180% since October 2016.
In the position of CEO since 2002
John Maraganore became CEO of the Company in 2002.
Maraganore will support the leadership transition in a consulting capacity through March 31, 2022 and will continue to contribute to Alnylam’s success as a member of the company’s Scientific Advisory Board.
Maraganore has served as the Company’s Chief Executive Officer and as a member of the Company’s board of directors since December 2002.
Maraganore also served as the Company’s President from December 2002 to December 2007.
From April 2000 to December 2002, Maraganore served as Senior Vice President, Strategic Product Development at Millennium Pharmaceuticals, Inc., a biopharmaceutical company (now Millennium: The Takeda Oncology Company).
Maraganore serves as a director of Agios Pharmaceuticals, Inc., as a member of the Board of the Biotechnology Innovation Organization (BIO), a non-profit biotechnology trade organization, of which he was previously Chair, and as a member of the BIO Executive Committee.
Maraganore formerly served as a director of bluebird bio, Inc.
Push-out Score determined
The Push-out Score™ determined by exechange gauges the pressure surrounding John Maraganore’s move on a scale of 0 to 10.
exechange reached out to Alnylam and offered the company the opportunity to comment on the score.
Read the full story in the exechange report 44.2021 ($).